RHO

Rhodopsin (definition: A light-sensitive protein in rod photoreceptors, produced by the RHO gene, that's essential for seeing in dim light.) sits inside rod cells at the back of the eye and lets them respond to light. The protein binds a vitamin-A-derived molecule called 11-cis retinal and is switched on when light strikes it, which is the first step in low-light vision. When RHO is altered, the rhodopsin protein often misfolds and builds up inside the cell, which stresses the rod and can lead to its death. RHO-related disease is usually inherited in an autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) pattern, meaning a single altered copy of the gene is enough to cause it. Because only one healthy copy is needed for normal rod function, researchers have explored silencing or correcting just the faulty copy. Rarer recessive forms, where two altered copies are involved, have also been described.

The most common presentation is retinitis pigmentosa, which typically begins with difficulty seeing at night and a gradual narrowing of side (peripheral) vision. Imaging studies of people with RHO-associated RP show that rod cells are disrupted first, with cone cells becoming disorganized as the disease front advances. How the disease looks and progresses can vary widely, even among relatives carrying the exact same variant. In one Portuguese family, the same RHO change caused typical widespread RP in some members and a limited sector form in another, with severity increasing with age. A specific variant, p.G90D, has been linked in different people to congenital stationary night blindness as well as to progressive sector, pericentral, and classic RP. Depending on where the change falls in the protein, people may show night blindness, rod-cone dystrophy, sector RP, or localized areas of retinal thinning. In a Japanese cohort, variants in one region of the gene ("class A") caused more severe disease and more frequent macular changes than variants in another region ("class B"). One study of driving ability suggested that people with RHO or HK1 mutations may lose visual field more slowly than some other genetic groups, though this needs further study.

RHO is a well-established cause of retinitis pigmentosa and is the single most common gene behind the dominant form of the disease. It is consistently one of the most frequently identified genes across inherited retinal disease cohorts around the world, including in the United States, India, and Pakistan. There is good evidence that the location and type of variant influences how severe the disease is and which pattern it typically follows. Laboratory models using patient-derived retinal cells show that a RHO variant can cause the protein to accumulate and trigger cellular stress pathways that harm rods.

Not every change found in RHO causes disease, and telling harmful variants apart from harmless ones remains a real challenge. A large analysis concluded that roughly two-thirds of rare missense changes in RHO are likely harmless, underscoring the need to evaluate each variant carefully. Researchers do not yet fully understand why the same variant can produce such different outcomes in different people, from stationary night blindness to advanced RP. Much of the newest work on how RHO disease damages the retina and how it might be corrected comes from animal and laboratory models, which do not always translate directly to people.

No therapy targeting RHO has been approved to date, but this gene is an active focus of research. A review of candidate RP gene therapies describes QR-1123, an antisense drug designed to silence the specific P23H rhodopsin (definition: A light-sensitive protein in rod photoreceptors, produced by the RHO gene, that's essential for seeing in dim light.) variant, as being under clinical investigation with encouraging laboratory results. In a large-animal (pig) model carrying the human P23H variant, a gene-editing tool called RHO1-2 cut only the faulty gene copy and preserved rod and cone function; this is promising early laboratory work, not an available treatment. In mouse studies of a sector-RP variant, reducing light exposure and a drug called fingolimod lessened retinal damage, suggesting possible protective strategies that still require testing in people. Other mouse and cell studies are working out how RHO variants injure the retina, including inflammation and cell-death pathways, to guide future therapies.

• Gene editing in a large-animal model

  Preclinical animal study (preprint).

  What was found:

  Treatment halted rod loss, restored rod-driven function, and preserved cones, and treated pigs could navigate a maze using rod vision a year later.

  Why it matters:

  It demonstrates a plausible strategy for correcting dominant RHO disease at its source in a large animal.

  Limitation: This is laboratory research in animals, not a treatment available to people, and results in humans are unknown.

• Sorting harmful RHO changes from harmless ones

  Observational human genetic analysis with literature review.

  What was found:

  Of 52 variants detected, only 17 were judged likely disease-causing, and the analysis suggested roughly two-thirds of rare missense changes and most truncating changes before a certain point are probably benign.

  Why it matters:

  It shows why careful, individual evaluation of each RHO variant is essential, even for a well-known gene.

  Limitation: Variant classification relies partly on prediction tools and existing databases, which can change as more data accumulate.

• Where a variant sits shapes disease severity

  Cross-sectional human cohort study.

  What was found:

  Class A patients had worse visual acuity, more retinal structural loss, and macular degeneration far more often than class B patients.

  Why it matters:

  It supports using variant location to help anticipate how the disease may behave, and the pattern held across different ethnic backgrounds.

  Limitation: The study was small and from a single center, so findings should be applied cautiously to individuals.

• One variant, many outcomes

  Human case series.

  What was found:

  Phenotypes ranged from stationary night blindness to sector, pericentral, and classic progressive RP, with over half developing progressive disease.

  Why it matters:

  It shows that a variant once thought to cause only stable night blindness can in fact lead to progressive retinal degeneration, which matters for counseling.

  Limitation: The findings apply to one specific variant and a limited number of families.

• Detailed imaging of rod and cone changes

  Human imaging study.

  What was found:

  Cone cells were irregular even in relatively preserved areas, and rod loss outpaced cone loss at the advancing edge of degeneration.

  Why it matters:

  Such precise measurements could serve as outcome markers in future treatment trials.

  Limitation: This is an emerging imaging technique reported in a brief study; broader validation is needed.

RHO disease is usually passed down in an autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) pattern, which means each child of an affected parent has a 50 percent chance of inheriting the altered copy. Because presentation varies even within a family, relatives who carry the same variant may be affected quite differently or at different ages, so relatives considering testing may benefit from genetic counseling. Although RHO disease can begin in adulthood, it is more often identified in children and adolescents, which is worth keeping in mind for younger family members.

• Which specific RHO variant was found, and how confident is the laboratory that it is disease-causing?
• Based on the variant's location, what pattern of vision changes has been reported for it?
• What baseline tests would help track my retina over time?
• Given the autosomal dominant inheritance, what does this mean for my children and other relatives?
• Are there any research studies or natural history studies relevant to RHO that I could learn more about?
• How often should my vision and retina be monitored?

Confirming the specific RHO variant and how it was classified can help clarify what is known about it, since interpretation of individual variants is central to this gene. A detailed eye examination, including field testing and retinal imaging, helps establish a personal baseline given how variable RHO disease can be. Discussing genetic testing results with a genetic counselor can help make sense of inheritance and variant meaning. For questions about research studies, RP Hope's Clinical Trials Finder can guide personalized screening with RHO in mind.